Trial Outcomes & Findings for Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy (NCT NCT00844714)

Results Overview

endothelial function as assessed by flow-mediated vasodilation of the brachial artery

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

20 participants

Primary outcome timeframe

12 weeks, 24 weeks

Results posted on

2015-06-26

Participant milestones
Measure	Rituxan Rituxan: 1000mg rituxan by intravenous infusion on day 1 and day 15
Overall Study STARTED	20
Overall Study COMPLETED	20
Overall Study NOT COMPLETED	0

Withdrawal data not reported

Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy

Baseline characteristics by cohort
Measure	Rituxan n=20 Participants Rituxan: 1000mg rituxan by intravenous infusion on day 1 and day 15
Age, Continuous	54 years n=5 Participants
Sex: Female, Male Female	1 Participants n=5 Participants
Sex: Female, Male Male	19 Participants n=5 Participants
Region of Enrollment United States	20 participants n=5 Participants
Flow-mediated vasodilation (FMD)	3.9 mm n=5 Participants

Timeframe: 12 weeks, 24 weeks

endothelial function as assessed by flow-mediated vasodilation of the brachial artery

Outcome measures
Measure	Rituxan n=20 Participants Rituxan: 1000mg rituxan by intravenous infusion on day 1 and day 15
Flow-mediated Vasodilation (FMD) 12 weeks	6.1 percentage change in diameter Interval 4.9 to 7.6
Flow-mediated Vasodilation (FMD) 24 weeks	4.4 percentage change in diameter Interval 3.3 to 6.1

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

University of California, San Francisco

Phone: 415-206-8257